Dangerous Drug: Miglitol(mig’ lah tall)
Glyset
PREGNANCY CATEGORY B
Drug Classes
Alpha-glucosidase inhibitor
Antidiabetic
Therapeutic Actions
An alpha-glucosidase inhibitor that delays the digestion of ingested carbohydrates, leading to a smaller increase in blood glucose following meals and a decrease in glycosylated Hgb; does not enhance insulin secretion and so its effects are additive to those of the sulfonylureas in controlling blood glucose.
Indications
Adjunct to diet and exercise to lower blood glucose in patients with type 2 diabetes mellitus whose hyperglycemia cannot be managed by diet and exercise alone
Combination therapy with a sulfonylurea to enhance glycemic control in those patients with type 2 diabetes who do not receive adequate control with diet and either drug
Contraindications and Cautions
Contraindicated with hypersensitivity to the drug; diabetic ketoacidosis; cirrhosis; inflammatory bowel disease; intestinal obstruction or predisposition to intestinal obstruction; colon ulceration; type 1 diabetes; conditions that would deteriorate with increased gas in the bowel, severe renal impairment.
Use cautiously with renal impairment, pregnancy, lactation.
Available Forms
Tablets—25, 50, 100 mg
Dosages
Adults
Monotherapy: Initial dose, 25 mg PO tid at the first bite of each meal; may start at 25 mg PO daily if severe GI effects are seen. After 4–8 wk, start maintenance, 50 mg PO tid at first bite of each meal. Maximum dose, 100 mg PO tid.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
